ADVISORY, March 30, 2017 (GLOBE NEWSWIRE) --
What: Neurotrope, Inc. (Nasdaq: NTRP ), a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer's disease, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Joshua N. Silverman, Chairman of the Board of Directors, will ring the Opening Bell.
Where: Nasdaq MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio
When: Friday, March 31, 2017 – 9:15 a.m. to 9:30 a.m. ET
Neurotrope Media Contact: Jeffrey Benison 212.334.8709 or 516.286.6099 jbenison@neurotropebioscience.com
Nasdaq MarketSite: Emily Pan (646) 441-5120 emily.pan@nasdaq.com
Feed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: http://www.facebook.com/NASDAQ .
For photos from ceremonies and events, please visit our Instagram page: http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page: http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page: http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page: http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's dementia and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.
The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by bryostatin-1, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's dementia.
Neurotrope is conducting a Phase 2 trial of bryostatin-1 in the treatment of moderate to severe Alzheimer's dementia, as well as preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.
About Nasdaq
Nasdaq (Nasdaq: NDAQ ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed companies with a market value of $10.1 trillion and nearly 18,000 corporate clients. To learn more, visit: business.nasdaq.com .
-NDAQA-
